Dec 11, 2022 / 03:00PM GMT
Operator
Hello, and welcome to the Aptose Biosciences Clinical Update and Data Review Conference Call and Webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Dan Ferry of LifeSci Advisors. Dan?
Daniel Ferry - LifeSci Advisors, LLC - MD & Relationship Manager
Thank you, operator. Good morning, and welcome to the Aptose Biosciences conference call and webcast. Earlier today, Aptose issued a press release relating to this clinical update and data results being presented today at ASH. The news release as well as related SEC filings are accessible on Aptose's website.
Joining me on today's call are Dr. William G. Rice, Chairman, President and CEO; and Dr. Rafael Bejar, Senior Vice President and Chief Medical Officer. Further, Dr. Naval Daver of MD Anderson Cancer Center, Global Lead Investigator for tuspetinib Phase I/II trial will be joining us for the question-and-answer session.
Before we proceed, I would like to remind everyone that certain statements made during
Aptose Biosciences Inc Corporate Update Call Transcript
Dec 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers